A Quality of Life and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years) With Atopic Dermatitis
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The study will evaluate the safety and effect of pimecrolimus cream 1% on quality of life of
caregivers of South African children with mild to moderate atopic dermatitis (AD).